A Pilot Study: Longer Duration of Posttransplant Hepatitis C Virus Therapy May Increase the Sustained Response Rate

Basit Öğe Kaydı
dc.contributor.authorKarasu, Z.
dc.contributor.authorAkay, S.
dc.contributor.authorYilmaz, F.
dc.contributor.authorAkarca, U.
dc.contributor.authorErsoz, G.
dc.contributor.authorGunsar, F.
dc.contributor.authorKilic, M.
dc.date.accessioned2019-10-27T20:48:38Z
dc.date.available2019-10-27T20:48:38Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground. Although end of treatment virological responses are similar in posttransplant patients with recurrent chronic hepatitis C virus infection and nontransplant patients, the sustained virological response rate is lower in the posttransplant setting. We investigated the efficacy of a longer duration (3 years) of therapy. Methods. Thirteen patients with biopsy-proven recurrent hepatitis C were included in the study. In the first year of therapy, all patients were treated with a standard regimen of interferon alpha 2b 3MU 3 times in a week plus ribavirin (800 to 1000 mg/d). After the availability of pegylated interferon, patients were converted to pegylated interferon (1.5 mu g/kg body weight). Hepatitis C virus RNA was evaluated at months 3, 6, 9, 12, 24, 36, and 42. If hepatitis C virus RNA was negative at month 12, the patients continued treatment for 36 months. Results. Hepatitis C virus RNA was negative in six patients at 12 months, including two who became hepatitis C virus RNA negative after 3 months; two, after 6 months; and two, after 12 months of therapy. Those six continued treatment completing 3 years of treatment with a sustained virological response. Four of those six patients with sustained virological response required colony-stimulating factors during treatment. Conclusion. Although the hepatitis C virus RNA status of patients at 12 weeks is a good marker to predict a sustained virological response in the nontransplant setting, it is not valid in posttransplant patients. A prolonged duration of therapy for patients who are viral responders at 12 months may prevent recurrence and increase the sustained virological response rate.en_US
dc.identifier.doi10.1016/j.transproceed.2009.06.212en_US
dc.identifier.endpage3809en_US
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.issue9en_US
dc.identifier.pmid19917392en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage3806en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2009.06.212
dc.identifier.urihttps://hdl.handle.net/11454/42743
dc.identifier.volume41en_US
dc.identifier.wosWOS:000272123900054en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleA Pilot Study: Longer Duration of Posttransplant Hepatitis C Virus Therapy May Increase the Sustained Response Rateen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu